Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516696 · ClinicalTrials.gov registry record · Phase 3
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT02516696: Clinical Trial Phase 3 study, sponsored by Weill Medical College of Cornell University.
NCT02516696 is a Phase 3 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02516696, a Phase 3 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
Primary Outcome
Calculate rate of progression-free survival for subjects following treatment BiRd regimen compared to Rd treatment regimen. Progression is determined by the International Myeloma Working Group Criteria.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-02 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 3 |
Why NCT02516696 stopped before completion
NCT02516696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02516696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02516696 about?
NCT02516696 is a clinical study titled "BiRd vs. Rd as Initial Therapy in Multiple Myeloma". This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatme...
What is the current status of trial NCT02516696?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2016-02. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT02516696?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT02516696?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02516696's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia